draft

Draft Research Plan

Screening for Depression, Anxiety, and Suicide Risk in Adults

Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

This document is available for Public Comments until Jun 03, 2020 08:00 PM

In an effort to maintain a high level of transparency in our methods, we open our Draft Research Plan to a public comment period before we publish the final version.

Leave a Comment >>

May 07, 2020

Return to In Progress page

This new topic incorporates and updates the evidence related to screening for and treatment of depression and suicide risk while adding evidence related to screening for and treatment of anxiety disorders and combination approaches that address more than one of these conditions.

  1. Do depression, anxiety, and suicide risk screening programs in primary care or comparable settings result in improved health outcomes in adults, including pregnant and postpartum persons?
  2. Does sending depression, anxiety, and suicide risk screening test results to providers (with or without additional care management supports) result in improved health outcomes?
  3. Do instruments to screen for depression, anxiety, and/or high suicide risk accurately identify adults, including pregnant and postpartum persons, with depression, anxiety, and high suicide risk in primary care or comparable settings?
  4. What are the harms associated with screening for depression, anxiety, and suicide risk in primary care or comparable settings in adults, including pregnant and postpartum persons?
  5. Does treatment of depression, anxiety, or high suicide risk (psychotherapy or pharmacotherapy) result in improved health outcomes in adults, including pregnant and postpartum persons?
  6. What are the harms of treatment of depression, anxiety, or high suicide risk (psychotherapy or pharmacotherapy) in adults, including pregnant and postpartum persons?

Contextual questions will not be systematically reviewed and are not shown in the Analytic Framework.

  1. What is the differential effect of screening for depression, anxiety, or suicide risk separately compared with screening for one or more of these conditions at the same time?
  2. What health care system supports (e.g., collaborative care) can help ensure appropriate diagnosis and followup, treatment engagement and retention, and improved outcomes?
  3. How well do suicide risk screening instruments predict future suicide attempts?
  4. What is known about the validity of the most commonly used or recommended instruments to screen for depression, anxiety, and suicide risk in U.S. racial/ethnic minority patients?

The Proposed Research Approach identifies the study characteristics and criteria that the Evidence-based Practice Center will use to search for publications and to determine whether identified studies should be included or excluded from the Evidence Review. Criteria are overarching as well as specific to each of the key questions.

  Include Exclude
Condition definitions
  • Major depressive disorder (including depression with peripartum onset or other specifiers).
  • Anxiety disorders addressed in this review will include
  • Suicidal ideation includes suicidal thoughts or plan for suicide.
  • Included studies may address these conditions individually or in combination.
Other mental health disorders (e.g., obsessive-compulsive disorder, posttraumatic stress disorder, psychotic disorders, bipolar disorder, cyclothymia, adjustment disorder with depressed mood, and other depressive disorders [persistent depressive disorder/dysthymia, disruptive mood dysregulation disorder, premenstrual dysphoric disorder, substance/medication-induced depressive disorder, depressive disorder due to another medical condition], and other anxiety disorders [agoraphobia, specific phobias, separation anxiety disorder, selective mutism, substance/medication-induced anxiety disorder, anxiety disorder due to another medical condition]).
Population KQs 1–3: Adults (age ≥19 years), including pregnant and postpartum persons. Trials may include:
  • Unselected primary care population.
  • Primary care patients without known depression or anxiety disorders or high risk of suicide.
  • Other comparable broad-based population recruited from a health care setting.

KQs 4, 5:

  • Adults (age ≥19 years), including pregnant and postpartum persons, with depressive disorders, anxiety disorders, or high risk of suicide, or with elevated symptoms of depression or anxiety. Sample must include an estimated 50% or more of participants with an included disorder, but may also include some participants with related (e.g., other depressive or anxiety disorders) or subsyndromal conditions (e.g., elevated symptoms but not meeting full criteria).
  • For anxiety and depression, evidence will be limited to studies that recruit primary care patients (or comparable broad-based health care recruitment), although treatment can take place in any outpatient setting, including primary care or specialty care (such as mental health). If evidence in primary care–recruited patients is limited for any condition-by-treatment approach combination, evidence will be extended to patients recruited from other settings.

All KQs: A priori subpopulations of interest include pregnant and postpartum persons, older adults, and individuals identified through population-based screening in primary care or community settings.

  • Children and adolescents (age ≤18 years). Trials in which >50% of the population are age ≤18 years will be excluded.
  • Studies limited to populations that are not broadly generalizable to primary care (e.g., persons with specific comorbid mental health conditions such as depression and substance use disorder); persons with other mood disorders (e.g., bipolar disorder, persistent depressive disorder/dysthymia); persons with concomitant medical conditions (e.g., cancer, traumatic brain injury, coronary artery disease, or postcardiovascular disease event); persons with developmental disorders; persons with physical disabilities; persons in the midst of a suicidal crisis, identified through their use of health care services related to self-harm (e.g., in the emergency department); persons in residential, institutional, or inpatient settings.
  • Studies of physician-assisted suicide in patients who are terminally ill.
Interventions KQs 1, 3: Screening interventions with or without additional provider or patient-facing elements such as referral support, treatment guidelines, symptoms monitoring, and standardized treatment. Screening tools must be brief standardized instruments designed to identify persons with depression, anxiety, and/or high risk of suicide; self-report, clinician-administered, or electronically delivered (<5 minutes for clinician-administered instruments, <15 minutes for self-administered instruments).

KQ 2: Limited to the most widely recommended or used screening tools:

  • For depression: Patient Health Questionnaire (PHQ), 2- and 9-item versions; Center for Epidemiologic Studies Depression Scale (CES-D); Edinburgh Postpartum Depression Scale (EPDS) for perinatal persons; Geriatric Depression Scale (GDS) for older adults.
  • For anxiety: Generalized Anxiety Disorder scale (GAD), in any form; PHQ Anxiety scale; EPDS-Anxiety subscale, for perinatal persons; Geriatric Anxiety Inventory (GAI) and Geriatric Anxiety Scale (GAS) for older adults.
  • For anxiety and depression: PHQ-ADS (combines the PHQ and GAD).
  • For suicide screening: Any brief tools.

KQs 4, 5: Intervention to address depression, anxiety, and/or risk of suicide, including

  • Counseling (e.g., psychotherapy, psychoeducation, means restriction)
  • First-line pharmacotherapy agents (selective serotonin reuptake inhibitors [SSRIs], selective serotonin norepinephrine reuptake inhibitors [SNRIs], serotonin modulators (e.g., vortioxetine, vilazodone, nefazodone), atypical agents (e.g., bupropion, mirtazapine), tricyclic antidepressants, buspirone, brexanolone (for postpartum depression only), lithium (for suicide risk only), benzodiazepines (for anxiety only)
  • Interventions must be conducted in primary care, referable from primary care, or feasible for implementation in a health care setting.
KQ 2: Other screening instruments.

KQs 4, 5:

  • Relapse prevention among persons with a history of mood disorders, other treatment modalities (e.g., exercise, light therapy, transcranial magnetic nerve stimulation, electroshock treatment, St. John’s wort, social marketing, policy, system-level interventions, or adjunctive agents to enhance the effects of antidepressants) except as optional adjunctive components to first-line approaches.
  • Intervention involving components that could not be replicated in most health care settings, including environmental components (media message, public signage) or that intervenes on groups in closed (pre-existing) social networks (e.g., in worksites, churches, clubs/teams), or involves potential notification or use of authority figures (e.g., military commanders, workplace supervisors).
  • Pharmacotherapeutic agents that are not approved by the U.S. Food and Drug Administration for depression or anxiety, or are no longer commonly used for anxiety and depression (e.g., monoamine oxidase inhibitors [including reversible monoamine oxidase A inhibitors for anxiety]).
Comparators KQs 1, 3 (Screening):
  • Usual care/no screening.
  • Screening with no feedback of results to providers.

KQ 2 (Diagnostic accuracy):

  • Reference standard (structured or semistructured diagnostic interview or a nonbrief [>5 minutes] unstructured interview with mental health clinician) within 2 weeks of screening in populations that include a full spectrum of patient severity for the given setting (i.e., studies cannot limit the patient pool to only nondepressed and known/highly likely depressed patients). Reference conditions include major depressive disorder, generalized anxiety disorder, social anxiety disorder, suicidal ideation, or any combination of the above.

KQs 4, 5 (Counseling):

  • Usual care/no intervention.
  • Waitlist.
  • Attention control.
  • Minimal intervention (e.g., usual care limited to no more than 15 minutes of information).

KQs 4, 5 (Pharmacotherapy):

  • Placebo (including placebo along with counseling, when compared with the active agent plus the same counseling intervention).
  • All those listed under “Counseling” above.
Active intervention (i.e., comparative effectiveness).
Outcomes KQs 1, 4:
  • Depression or anxiety symptoms, remission or diagnosis, or response.
  • Suicide deaths, self-harm (i.e., suicide attempts), or suicidal ideation.
  • All-cause mortality.
  • Quality of life.
  • Functioning (including days of missed work).
  • Change in health status (e.g., improvement in comorbid conditions or reduction in physical complaints).
  • Child/infant outcomes in trials of pregnant or postpartum parents (continuation of breastfeeding, achievement of recognized developmental milestones, reduced abuse or neglect).
  • Emergency department visits or inpatient stays.
  • Hopelessness.

KQ 2: Sensitivity, specificity, or data to calculate one or both.

KQs 3, 5:

  • Treatment avoidance.
  • Deterioration in patient-provider relationship.
  • Labeling or stigma.
  • Inappropriate or unnecessary treatment.
  • Other harms reported by screening and treatment trials.
  • Paradoxical worsening of mental health symptoms.

KQ 5 (Pharmacotherapy only):

  • Serious adverse effects.
  • Withdrawals due to adverse effects.
  • Suicidality.
  • Serotonin syndrome.
  • Cardiac effects.
  • Seizures (bupropion only).
  • Dependence (benzodiazepines only).
  • Thyroid or renal toxicity (lithium only).
  • For pregnant persons only: fetal/infant harms (neonatal death, major malformations, small for gestational age/low birth weight, preeclampsia).
KQs 1, 4: Rate of identification of persons with depression, anxiety, or high risk of suicide (e.g., trials of clinician training to identify persons at high risk of suicide that report no patient outcomes).
Outcome assessment timing KQs 1, 3–5: ≥6 weeks after baseline, except for suicide death or self-harm (no minimum followup).

KQ 5 (Harms of pharmacotherapy): No minimum followup.

KQ 2: Maximum of 2 weeks between screening and reference standard.
 
Setting KQs 1–3: Primary care settings (e.g., internal medicine, family medicine, obstetrics/gynecology, pediatrics [for postpartum screening], family planning, military health clinics, university-based health clinics) or comparable (e.g., identification through health plan administrative databases).

KQs 4, 5:

  • Intervention may be implemented in outpatient health care (primary or specialty, including mental health).
  • Participants must be recruited from a primary care or comparable broad health care setting. If evidence in these patients is limited, evidence in patients recruited from specialty care will be used (e.g., mental health, virtual, or community settings).
KQs 1–3:
  • Community settings.
  • Mental health clinics (unless recruitment is through primary care screening).
  • Inpatient/residential facilities.
  • Correctional facilities.
  • Schools (other than school-based health clinics).

KQs 4, 5:

  • Correctional facilities.
  • Schools (other than school-based health clinics).
  • Worksites.
  • Inpatient/residential facilities.
  • Emergency departments.
Study design KQs 1, 3: Randomized, controlled trials; controlled clinical trials

KQ 2: Systematic reviews and studies of diagnostic accuracy reporting sensitivity and specificity (or comparable statistics) compared with an independently assessed gold standard (structured or semistructured diagnostic interview or a nonbrief [>5 minutes] unstructured interview with mental health clinician) within 2 weeks of screening in populations that include a full spectrum of patient severity for the given setting (i.e., studies cannot limit the patient pool to only nondepressed and known/highly likely depressed patients).

KQ 4:

  • Systematic reviews of controlled trials of interventions for depression, comparing active agents with control groups.
  • Randomized, controlled trials of anxiety interventions in primary care populations.
  • Systematic reviews of controlled trials of anxiety interventions, comparing active agents with control groups, if primary literature in primary care populations is insufficient.
  • Randomized, controlled trials of suicide prevention interventions.

KQ 5:

  • Systematic reviews of controlled trials comparing active agents with control groups
  • Systematic reviews of comparative cohort and case-control observational studies
  • (Harms of pharmacotherapy only): large comparative cohort and case-control observational studies published after identified systematic reviews that include observational studies.
All KQs: All other study designs.

KQ 2: If unable to limit to existing systematic reviews, case-control studies will be used (i.e., studies that limit the study sample to only participants with and without known mental health symptoms).

Study geography Reviews and primary studies that primarily take place in countries categorized as “Very High” on the 2018 Human Development Index (as defined by the United Nations Development Programme) (published 2019). Reviews in which >50% of included studies take place in countries not categorized as “Very High” on the Human Development Index.
Publication language English Any language other than English
Publication year 1980 or later Prior to 1980
Quality rating Fair or good-quality studies Poor-quality studies